Dx firm Nanosphere launches $25.2M offering

Nanosphere ($NSPH) is looking to expand, offering 10.5 million shares of common stock priced at an 8% discount of $2.40 apiece.

The diagnostics company is looking to raise $25.2 million in the public offering, money it will use to fund working capital and corporate expenses.

Nanosphere's shares have skyrocketed by 78% this year, The Wall Street Journal reports, and the company is expecting its second-quarter revenue to double that of 2011. Nanosphere recently snagged FDA clearance for a new blood culture test, and the firm added 25 lab and hospital placements in Q2, bringing its total to 166, according to the WSJ.

The company continues to expand its Verigene platform for molecular diagnostics, offering infectious-disease, pharmacogenetic and microbiological tests, among others. The firm was founded in 2000 based on nanotechnological work by researchers at Northwestern University.

- read Nanosphere's release
- get more from the WSJ

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.